Sign In

Welcome to SN Connect, the new gold standard for HCP-focused media.

Sign Up

The Impact of EMBER-3 & Imlunestrant Changing Practice: Better Data for Women With Advanced ER+/HER2- Breast Cancer

How Belantamab Mafodotin Is Changing Myeloma Treatment: Comparing Data From The DREAMM-7 & DREAMM-8 Trials

Breakthrough Hope: A Revolutionary Advance in Glioma Treatment After 20 Years

The Impact of EMBER-3 & Imlunestrant Changing Practice: Better Data for Women With Advanced ER+/HER2- Breast Cancer

How Belantamab Mafodotin Is Changing Myeloma Treatment: Comparing Data From The DREAMM-7 & DREAMM-8 Trials

Breakthrough Hope: A Revolutionary Advance in Glioma Treatment After 20 Years

A Better Option For Some Women With Advanced HR+, HER2- Breast Cancer: Unpacking The SERENA-6 Trial

Adding Durvalumab Keeps Gastric Cancer Under Control Longer, MATTERHORN Trial Shows

Osimertinib (Tagrisso) Leads To More Tumor Shrinkage For EGFR+ Lung Cancer Patients

The DESTINY Trial Confirms Top Second-Line Approach For HER2+ Advanced Gastric Cancer

BREAKWATER Trial Highlights Importance Of Early Biomarker Testing In Colon Cancer

DESTINY Updates: New Drug Combo May Keep HER2+ Metastatic Breast Cancer Under Control For Longer

BREAKWATER Trial Highlights Importance Of Early Biomarker Testing In Colon Cancer

Asciminib: A New Era in Treating Newly Diagnosed Chronic Myeloid Leukemia

Avutometinib Plus Defactinib Gets Accelerated Approval for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Talvey: A Promising Treatment for Relapsed/Refractory Multiple Myeloma

Post-Vorasidenib Approval: Practical Insights for Use in IDH-Mutant Low-Grade Gliomas

Kisqali Approval: Weighing the Risks vs. Benefits for Early-Stage Breast Cancer

Biomarker Testing in Lung Cancer - It Must Be Standard Of Care

Lung Cancer - The Nuances of Mutations & Targeted Therapies

Sarclisa Gets FDA Approval for Newly Diagnosed Multiple Myeloma — When to Use a Four-Drug Regimen

Osimertinib: A New Standard of Care for Stage III EGFR-Mutated Non-Small Cell Lung Cancer

Integrating Genetic Testing and PARP Inhibitors in Prostate Cancer Management

Unprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients

Study Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care

Elahere: A Practice-Changing Option for Platinum-Resistant, FRα-Positive Ovarian Cancer

How Will Federal Budget Cuts Affect The Future Of Cancer Research?

Systemic Therapy for Advanced Gastric Cancer: Current Approaches and Emerging Strategies

The Controversy Around Radiation Oncologists, Medical Oncologists & the Use of Vorasidenib for Gliomas

Natural Killer Cells: Is This The Next Generation of Immunotherapy? Understanding The FDA Approval in Bladder Cancer

When to Order Immunohistochemistry Testing: With Tailored Therapies for HER2-Positive Cancers, IHC is More Relevant for More Patients

Yale’s Chief of Breast Oncology Shares Risk Stratification & Recommendations for CDK4/6 Inhibitors

Criteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma

Research Shows the Best Way to Discuss Clinical Trials With Patients & Boost Trust, Confidence

Integrating Genetic Testing and PARP Inhibitors in Prostate Cancer Management

Treating Prostate Cancer: The Value Of A Team Approach

For HR+/HER2- Early-Stage Breast Cancer at Increased Risk of Recurrence, Kisqali Has Benefits: Study

A Powerful Tool: Integrating Venetoclax into CLL Management Improves Survival

Oncologists Weigh in on Optimal Use of CDK 4/6 Inhibitors as Adjuvant Therapy in Early Breast Cancer

Imfinzi Improves Overall & Progression-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer

Balversa's FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer

Unprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients

Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval

For Women With Heavily-Treated Triple-Negative or HR+, HER2- Metastatic Breast Cancer, Enfortumab Vedotin (Padcev) Shows Some Anti-Tumor Activity

Understanding Pluvicto (Lutetium-177) and PSMA PET Scans in Prostate Cancer Treatment

Elahere for Ovarian Cancer: Prevention, Detection & Management of Ocular Adverse Events

Nearly 50% Skip Prescribed Breast Cancer Meds — Physicians Should Focus on Education & Cutting Costs

New ASCO Guidelines Offer a Practice-Changing Approach for PIK3CA/AKT1/PTEN Metastatic Breast Cancer

Study: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates

Why Physicians Should Prioritize Emotional Wellbeing

The issue of burnout has long plagued physicians given the many hours of physically and mentally draining work. But with the recent Covid pandemic and the resulting changes to the industry, the demands on doctors is even higher — and many may be experiencing profession-related mental health issues.

Now more than ever, it’s important to pay attention to the idea of compassion fatigue, says Dr. Marianna Strongin, a licensed clinical psychologist and founder of Strong in Therapy, her Manhattan-based private practice.

Close the Gap 2024 - Addressing Disparities in Cancer Care & Improving Outcomes for Patients

Community Engagement & Resources are Key to ‘Closing the Gap’ on Racial Disparities in Cancer Care

Meeting the Needs of Black Caregivers